Randomized Trial of Chemotherapy Versus Chemotherapy Plus Radiotherapy for Stage I–II Hodgkin's Disease

A total of 277 patients with untreated Hodgkin's disease, clinical stages I-II, were randomized to cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) alone for 6 monthly cycles or to CVPP plus radiation therapy (RT), 3,000 rad, to involved areas (CVPP plus RT). One or more of th...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1988-11, Vol.80 (18), p.1466-1473
Main Authors: Pavlovsky, Santiago, Maschio, Mabel, Santarelli, Maria Teresa, Muriel, Federico Sackmann, Corrado, Claudia, Garcia, Ibette, Schwartz, Laura, Montero, Carlos, Sanahuja, Francisco Lobo, Magnasco, Osvaldo, Raha, Roberto, Cavagnaro, Fernando
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols
Biological and medical sciences
Chemotherapy
Child
Child, Preschool
Combined Modality Therapy
Female
Hodgkin Disease - drug therapy
Hodgkin Disease - radiotherapy
Hodgkin Disease - therapy
Humans
Infant
Lomustine - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prednisone - therapeutic use
Procarbazine - therapeutic use
Prognosis
Random Allocation
Remission Induction
Statistics as Topic
Vinblastine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 277 patients with untreated Hodgkin's disease, clinical stages I-II, were randomized to cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) alone for 6 monthly cycles or to CVPP plus radiation therapy (RT), 3,000 rad, to involved areas (CVPP plus RT). One or more of the following factors were considered as unfavorable prognosis: age >45 years, more than two lymph node areas involved, or bulky disease. In the favorable group, disease-free survival (77% vs. 70%) or overall survival (92% vs. 91%) at 84 months for CVPP versus RT plus CVPP was similar. Patients with unfavorable prognosis treated with RT plus CVPP had longer disease-free survival (75% vs. 34%) (P ═.001) and overall survival (84% vs. 66%) than patients treated with CVPP alone. [J Natl Cancer Inst 1988;80:1466–1473]
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/80.18.1466